When you are a cultivator or engaged in a side-business in cannabis production, first of all, you must understand that the government with the trial period tries to get a plant as close to a drug standard as possible.
Anyone who deals with living material and the change processes that go with it, knows that it takes only very small deviations in a process before a standard is no longer a standard.
Soil, light, water, heat, harvest time and much more influences the content of cannabinoids and terpenes. As soon as the material is harvested, the cannabinoid and terpene change, e.g. cannabinoids change from acid form to non-acid form, e.g. THC-A to THC.
One has to keep in mind that the acid form is as medically active as a non-acidic form, it just has another medical effect. This means that the cannabinoids are equally active without heating, storage and sunlight after harvest, you just get a different kind of medicine.
Standardization in cannabis for medicinal use is crucial to the outcome, where even small changes can affect complicated diseases. Some people and diseases are more sensitive to deviations than others.
For example, in Israel, a pre-clinical project was conducted against externalizing autism children. The first batch worked really well, while the second batch put the children back to the externalizing behavior. The product was from the same producer and from the same genetic plant. The only difference that could be found was the season for cultivation and harvest, which had resulted in a small impact on the cannabinoid and terpene composition, but big enough for it to be completely wrong for the target group.
This is one of the reasons why we at Cannabis Danmark have a desire to make sure that it is possible to read other information than just THC and CBD content on the label.
If you can standardize your products with very few deviations, it is also these products that are most suitable for research and interesting for doctors to prescribe. This gives a competitive edge.
An Israeli innovation company, Syqe, thus chose to test its vaporizer with Dutch cannabis from Bedrocan, as the company found that Israeli products were not standardized sufficiently.